Funding profile · Cancer immunotherapy

Kopra Bio

A UCSF viral therapy spinout with a $9.1 million seed round announced in June 2026, a $100,000 non-dilutive award, and no Form D filed under its own name as of this writing.

Data as of September 25, 2026. Company-reported and aggregator figures are labeled.

Rounds at a glance

What the filings show

No SEC Form D appears under Kopra Bio, Inc. or any obvious variant of its name as of September 25, 2026. The one formal public filing located is its state business registration.

Reading the record

1. No Form D is on file.A $9.1M institutional round with named lead investors would typically generate a Form D within 15 days of the first sale under Regulation D. None has been found under Kopra Bio’s name. Companies raising through simple agreements for future equity, as Y Combinator companies commonly do for their initial round, or under other exemptions, do not always file one, so the absence is a gap in the record rather than proof the round did not close.
2. One person holds every officer title.The 2024 state filing lists Andrew Bartynski as CEO, CFO and secretary all at once, a common structure for a company with a handful of people. Scientific cofounder Alexander Haddad and the UCSF faculty cofounders are not listed as corporate officers in this filing.
3. Aggregators disagree because they are looking at different moments.Tracxn’s snapshot, taken in January 2025 before the seed round closed, shows total funding of $500K. PitchBook’s more current profile puts total funding at $9.7M and lists 20 investors, only five of them named. The difference is almost entirely the $9.1M seed that closed in June 2026, after Tracxn’s snapshot was taken.
4. Non-dilutive and in-kind support sit outside the cash totals.The $100,000 QB3 award and the Charles River Incubator Program’s services are not part of either the $500K or the $9.1M figures reported elsewhere. Neither is the proposed King Faisal Specialist Hospital arrangement, which is structured as in-kind contributions for equity rather than a cash check, and which remains a memorandum of understanding rather than a signed, funded agreement.
5. The company’s own website says little.As archived in July 2026, kopra.bio consists of a name, a one-line tagline, a contact email and a row of investor or partner logos with no funding figures, named investors or team page. The funding numbers in this profile come entirely from press coverage and aggregators, not from the company’s own site.

Commercial signals

What to watch

• A Form D for the $9.1M seed round, or an amended filing that clarifies amount sold versus offered.
• Whether the King Faisal MOU converts into a funded, signed trial agreement.
• Named investors beyond the five reported by aggregators.
• Whether the China Phase I trial opens and what it costs to run.

The Kopra Bio story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Biodock: Shared investor: Andreessen Horowitz. A cloud platform that lets a biologist train an image-analysis model without writing code
• FidoCure: Shared investor: Andreessen Horowitz. A tumor sequencing service that routes dogs with cancer toward human targeted therapy drugs, compounded to canine doses
• Experiment: Shared investor: Andreessen Horowitz. A crowdfunding site where a graduate student can raise three thousand dollars in a month instead of waiting a year for a grant
• Science Exchange: Shared investor: Andreessen Horowitz. A marketplace for ordering experiments that became procurement software for big pharma, and that sourced the laboratories for the largest public test of whether

Sources

1. Public recordKopra Bio, Inc. business entity filing, document number 6345654California Secretary of State · filed Aug 13, 2024
2. IndependentExclusive: UCSF spinout nets $9.1M to test virus therapy for brain cancer in ChinaEndpoints News, Ryan Cross · Jun 16, 2026
3. IndependentGlioblastoma Treatment: UCSF Startup Turns Brain Tumors Into Immune Cell FactoriesTech Times, Maxwell Templeton · Jun 16, 2026
4. IndependentKopra Bio raises $9.1M seed to test virus therapy in brain cancerDealroom.co · Jun 16, 2026
5. IndependentKopra Bio Wins $100K Award from QB3 for Proof-of-Concept Development of Breakthrough Viral Therapy for CancerQB3, Kaspar Mossman · Jan 10, 2025
6. IndependentCharles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program CohortCharles River Laboratories, via Stock Titan · Dec 11, 2025
7. IndependentKFSHRC and Kopra Bio Sign MoU to Accelerate Viral-Vector Oncology and Launch Glioblastoma Program in Saudi ArabiaEIN Presswire, via The National Law Review · Oct 30, 2025
8. IndependentKopra Bio company profilePitchBook · accessed Sep 25, 2026
9. IndependentKopra Bio company profile and funding snapshotTracxn · snapshot Jan 15, 2025
10. IndependentKopra Bio, Inc. filing informationBizprofile, from the California Secretary of State registry · accessed Sep 25, 2026
11. CompanyKopra Bio homepagekopra.bio, via Internet Archive · captured Jul 25, 2026
12. CompanyKopra Bio company pageY Combinator · accessed Sep 25, 2026

Compiled from California Secretary of State records and published reports as of September 25, 2026. No SEC Form D notice was located for Kopra Bio. Reported amounts reflect the announcement or aggregator snapshot date and may not capture later sales or corrections. Healthcare Venture Capital Fund holds no position in Kopra Bio. This page is not an offer to sell or a recommendation to buy any security.